Trials Sponsors Conditions Drugs Pricing

Conditions

Schizophrenia Relapse

Outcome Measures

Primary Outcomes (1)

Number of Participants With Relapse
The definition of relapse is as follows 1.50% or greater increase in total DIEPSS score, 2. an increase in the total PANSS score of 25% or more from baseline, 3. deliberate self-injury, 4. emergence of clinically significant suicidal ideation, 5. violent behavior resulting in clinically significant injury to another person or property damage.
One year after the baseline cognitive function test or three months after the end of dose reduction, whichever came first.

Study Arms (1)

reduction group

EXPERIMENTAL

dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week

Drug: reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine

Interventions

reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazineDrug

reduction group

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age20 Years - 70 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

inpatients with a diagnosis of schizophrenia, and
those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000-mg chlorpromazine eq./day.

You may not qualify if:

Sponsors & Collaborators

Juntendo University
Otherlead

MeSH Terms

Interventions

HaloperidolOlanzapineQuetiapine FumarateAripiprazolePaliperidone PalmitateMethotrimeprazinePerphenazine

Intervention Hierarchy (Ancestors)

ButyrophenonesKetonesOrganic ChemicalsBenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Results Point of Contact

Title: Dr. Ryota Ataniya
Organization: Okada hospital

Study Officials

Takahashi Tadashi
Okada hospital
STUDY CHAIR
Mikiro Saito
Okada hospital
STUDY CHAIR

Publication Agreements

PI is Sponsor Employee: Yes

Enrollment

139 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Clinician, graduate student

Study Record Dates

First Submitted

January 11, 2017

First Posted

January 13, 2017

Study Start

April 2011

Date type not reported

This date has not been verified as actual or estimated.

Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Results Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

reduction group

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Results Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

reduction group

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

Source record